Target family: 1B. Retinoic acid receptors (type: nhr)
Target: Retinoic acid receptor-&gamma;

Ligand: TTNPB (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.82 pIC50
Reference (Journal): Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping.
Published in: Mol Cell Biol

Ligand: TTNPB (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.82 pIC50
Reference (Journal): Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
Published in: J Mol Biol

Ligand: trifarotene (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2019)
Primary target: yes
Median affinity: 8.109999656677246 pEC50
Reference (Journal): Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne.
Published in: Bioorg Med Chem Lett

Ligand: tretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity: 9.600000381469727 pKd
Reference (Journal): Activation of retinoid X receptors induces apoptosis in HL-60 cell lines.
Published in: Mol Cell Biol

Ligand: tretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity: 9.600000381469727 pKd
Reference (Journal): Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping.
Published in: Mol Cell Biol

Ligand: tretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity: 9.600000381469727 pKd
Reference (Journal): Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids.
Published in: Proc Natl Acad Sci USA

Ligand: tretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity: 9.600000381469727 pKd
Reference (Journal): Therapeutic applications for ligands of retinoid receptors.
Published in: Curr Pharm Des

Ligand: tretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity: 9.600000381469727 pKd
Reference (Journal): Structural basis for isotype selectivity of the human retinoic acid nuclear receptor.
Published in: J Mol Biol

Ligand: tretinoin (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity: 9.699999809265137 pEC50
Reference (Journal): Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
Published in: Bioorg Med Chem Lett

Ligand: tazarotene (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity: 7.400000095367432 pEC50
Reference (Journal): Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
Published in: Bioorg Med Chem Lett

Ligand: tamibarotene (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity: 6.230000019073486 pEC50
Reference (Journal): Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Published in: J Med Chem

Ligand: [3H]9-cis-retinoic acid (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pKd
Reference (Journal): Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids.
Published in: Proc Natl Acad Sci USA

Ligand: Ro 40-6055 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.889999866485596 pEC50
Reference (Journal): Novel non-carboxylic acid retinoids: 1,2,4-oxadiazol-5-one derivatives.
Published in: Bioorg Med Chem Lett

Ligand: palovarotene (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: Canada (2022), FDA (2023)
Primary target: yes
Median affinity:  -

Ligand: MM 11253 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids.
Published in: Oncogene

Ligand: CD666 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 7.17 pKd
Reference (Journal): Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma.
Published in: Biochem Biophys Res Commun

Ligand: CD2665 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.1 pIC50
Reference (Journal): Induction of apoptosis by retinoids and retinoic acid receptor gamma-selective compounds in mouse thymocytes through a novel apoptosis pathway.
Published in: Mol Pharmacol

Ligand: BMS493 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7 pIC50
Reference (Journal): Co-regulator recruitment and the mechanism of retinoic acid receptor synergy.
Published in: Nature